A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients

BRCA1/2 are tumour-suppressor genes involved in DNA homologous recombination and ovarian cancer development.  The study evaluated the risk of tumor cancer in women presenting the BRCA mutations. Risk-reducing surgery (RRS) was performed in 100 patients carrying BRCA1 (aged between 30-73 years, media...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta bio-medica : Atenei Parmensis 2022-08, Vol.93 (4), p.e2022051
Hauptverfasser: Loizzi, Vera, Cicinelli, Ettore, Del Vecchio, Vittoria, Arezzo, Francesca, Deromemaj, Xheni, Kardhashi, Anila, Paradiso, Angelo, Legge, Francesco, Natalicchio, Maria Iole, Resta, Leonardo, Resta, Nicoletta, Loconte, Daria Carmela, Cormio, Gennaro
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BRCA1/2 are tumour-suppressor genes involved in DNA homologous recombination and ovarian cancer development.  The study evaluated the risk of tumor cancer in women presenting the BRCA mutations. Risk-reducing surgery (RRS) was performed in 100 patients carrying BRCA1 (aged between 30-73 years, median age was 51 years) and BRCA 2 mutation (aged between 36-70 years, median age was 53 years). Fifty-eight patients had previous history of breast cancer. Between the 100 patients, 82 women underwent risk-reducing salpingo-oophorectomy (RRSO) through a laparoscopic minimally invasive approach, 7 (7 %) underwent laparoscopic RRSO and contextual hysterectomy, 1 woman (1 %) underwent RRSO through a laparotomic approach and 10 women (10 %) laparotomic RRSO and hysterectomy. During 5 (5 %) laparoscopic RRSO, prophylactic bilateral mastectomy was also performed. Early and late complication occurred in 3 patients (3 %). Two patients (2 %) were found to have occult Serous Tubal Intraepithelial Carcinoma (STIC) and three patients (3 %) occult cancer. RRSO is safe and feasible in BRCA mutation carriers. The procedure is effective for genetic prevention of ovarian cancer.
ISSN:0392-4203
2531-6745
DOI:10.23750/abm.v93i4.11695